{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T14:19:00Z","timestamp":1787667540629,"version":"build-2736575974"},"reference-count":42,"publisher":"BMJ","issue":"5","license":[{"start":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T00:00:00Z","timestamp":1748476800000},"content-version":"unspecified","delay-in-days":28,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"National Cancer Institute, National Institutes of Health","award":["75N91019D00024"],"award-info":[{"award-number":["75N91019D00024"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2025,5,1]]},"published-print":{"date-parts":[[2025,5]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Strategies for deploying indoleamine 2,3-dioxygenase 1 (IDO1)-targeted therapies for use against cancer have focused on IDO1\u2019s role in promoting peripheral immune tolerance that shields tumors from effector T cells. However, preclinical investigation of both primary and metastatic tumor development in the lungs has uncovered a previously unappreciated role for IDO1 in directing a counterregulatory response to interferon (IFN)-\u03b3 that realigns the local inflammatory environment to promote tumor neovascularization. Understanding how to therapeutically leverage the ability of IDO1 inhibitors to subvert inflammatory neovascularization within the tumor microenvironment has potential ramifications for future clinical development of these compounds.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Pulmonary metastases seeded by orthotopically implanted 4T1 breast carcinoma cells were evaluated by confocal microscopy for the impact of both genetic and pharmacological IDO1 inhibition, alone or in combination with ischemia-directed cytotoxic agents, on markers of blood vessel density, hypoxia and cell death. Tumor immunogenicity and programmed death-ligand 1 (PD-L1) elevation were also evaluated. Quantitative analysis of these results was used to guide combinatorial treatment regimen development.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Inhibiting IDO1 activity resulted in reduced neovascular density and elevated hypoxia in pulmonary metastases for which host IFN-\u03b3 was essential while adaptive immunity was dispensable. The tumors were consequently sensitized to the cytotoxic activity of ischemia-targeted agents including the protein kinase R-like endoplasmic reticulum kinase (PERK) inhibitor GSK2656157, the dithiol oxidative antimetabolite TTL-315, and the hypoxia-activated prodrug evofosfamide. Evofosfamide provoked the greatest degree of immunogenic cell death, while hypoxia, among other stressors, induced PD-L1. Based on this information, synergistic improvement in median survival was demonstrated in mice with established lung metastases through combined administration of anti-programmed cell death protein-1 (PD-1) antibody with evofosfamide and the IDO1 inhibitor epacadostat.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Improving therapeutic outcomes for patients with lung tumors, arising either as primary lesions or metastatic colonies, is of vital clinical importance. Building on preclinical evidence for IDO1\u2019s role in promoting inflammatory neovascularization of lung tumors, this study demonstrates how the intratumoral ischemic stress elicited by IDO1 inhibition can potentiate the immunogenic cytotoxicity of ischemia-targeted agents to effectively leverage immune checkpoint blockade responsiveness to confer a synergistic survival benefit. These findings provide a novel perspective on how IDO1 inhibitors can impact tumor biology and open up new possibilities for therapeutic applications.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jitc-2024-011398","type":"journal-article","created":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T04:45:19Z","timestamp":1748580319000},"page":"e011398","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":6,"title":["Neovascular pruning by IDO1 inhibitors can potentiate immunogenic cytotoxicity of ischemia-targeted agents to synergistically enhance anti-PD-1 responsiveness"],"prefix":"10.1136","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-8556-289X","authenticated-orcid":false,"given":"Shih-Chun","family":"Shen","sequence":"first","affiliation":[{"name":"Lankenau Institute for Medical Research, Wynnewood, Pennsylvania, USA"},{"name":"Drexel University College of Medicine, Philadelphia, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Souvik","family":"Dey","sequence":"additional","affiliation":[{"name":"WuXi Advanced Therapies, Philadelphia, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James B","family":"DuHadaway","sequence":"additional","affiliation":[{"name":"Lankenau Institute for Medical Research, Wynnewood, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika","family":"Sutanto-Ward","sequence":"additional","affiliation":[{"name":"Lankenau Institute for Medical Research, Wynnewood, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurice T","family":"Hampton","sequence":"additional","affiliation":[{"name":"Telesis Therapeutics, Inc, Philadelphia, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serguei V","family":"Kozlov","sequence":"additional","affiliation":[{"name":"Center for Advanced Preclinical Research, Frederick National Laboratory for Cancer Research, Sponsored by the National Cancer Institute, Frederick, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George C","family":"Prendergast","sequence":"additional","affiliation":[{"name":"Lankenau Institute for Medical Research, Wynnewood, Pennsylvania, USA"},{"name":"Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania, USA"},{"name":"Department of Pathology, Anatomy and Cell Biology, Thomas Jefferson University, Philadelphia, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7854-6933","authenticated-orcid":false,"given":"Alexander J","family":"Muller","sequence":"additional","affiliation":[{"name":"Lankenau Institute for Medical Research, Wynnewood, Pennsylvania, USA"},{"name":"Drexel University College of Medicine, Philadelphia, Pennsylvania, USA"},{"name":"Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,5,30]]},"reference":[{"key":"2026052723003309000_13.5.e011398.1","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11071010","article-title":"Lung-Seeking Metastases","volume":"11","author":"Stella","year":"2019","journal-title":"Cancers (Basel)"},{"key":"2026052723003309000_13.5.e011398.2","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-12-0014"},{"key":"2026052723003309000_13.5.e011398.3","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.78.1.129"},{"key":"2026052723003309000_13.5.e011398.4","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.ebiom.2016.11.013","article-title":"IDO1 is an Integral Mediator of Inflammatory Neovascularization","volume":"14","author":"Mondal","year":"2016","journal-title":"EBioMedicine"},{"key":"2026052723003309000_13.5.e011398.5","doi-asserted-by":"publisher","DOI":"10.1038\/35074122"},{"key":"2026052723003309000_13.5.e011398.6","doi-asserted-by":"publisher","DOI":"10.1016\/S0952-7915(03)00007-4"},{"key":"2026052723003309000_13.5.e011398.7","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1165298","article-title":"IDO1 and inflammatory neovascularization: bringing new blood to tumor-promoting inflammation","volume":"13","author":"Muller","year":"2023","journal-title":"Front Oncol"},{"key":"2026052723003309000_13.5.e011398.8","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2016.01.002"},{"key":"2026052723003309000_13.5.e011398.9","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-014-1549-4"},{"key":"2026052723003309000_13.5.e011398.10","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-12-3109"},{"key":"2026052723003309000_13.5.e011398.11","doi-asserted-by":"crossref","first-page":"7372","DOI":"10.18632\/oncotarget.7058","article-title":"Antimetabolite TTL-315 selectively kills glucose-deprived cancer cells and enhances responses to cytotoxic chemotherapy in preclinical models of cancer","volume":"7","author":"DuHadaway","year":"2016","journal-title":"Oncotarget"},{"key":"2026052723003309000_13.5.e011398.12","doi-asserted-by":"crossref","first-page":"636892","DOI":"10.3389\/fphar.2021.636892","article-title":"The Hypoxia-Activated Prodrug TH-302: Exploiting Hypoxia in Cancer Therapy","volume":"12","author":"Li","year":"2021","journal-title":"Front Pharmacol"},{"key":"2026052723003309000_13.5.e011398.13","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0806173105"},{"key":"2026052723003309000_13.5.e011398.14","article-title":"Mouse 4T1 breast tumor model","volume":"Chapter 20","author":"Pulaski","year":"2001","journal-title":"Curr Protoc Immunol"},{"key":"2026052723003309000_13.5.e011398.15","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-20-0226"},{"key":"2026052723003309000_13.5.e011398.16","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-13-3239"},{"key":"2026052723003309000_13.5.e011398.17","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-17-2285"},{"key":"2026052723003309000_13.5.e011398.18","first-page":"6201","article-title":"Remarkable tolerance of tumor cells to nutrient deprivation: possible new biochemical target for cancer therapy","volume":"60","author":"Izuishi","year":"2000","journal-title":"Cancer Res"},{"key":"2026052723003309000_13.5.e011398.19","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.tiv.2012.08.012","article-title":"A bioactive probe of the oxidative pentose phosphate cycle: novel strategy to reverse radioresistance in glucose deprived human colon cancer cells","volume":"27","author":"Li","year":"2013","journal-title":"Toxicol In Vitro"},{"key":"2026052723003309000_13.5.e011398.20","doi-asserted-by":"crossref","DOI":"10.1186\/s13058-019-1189-x","article-title":"Targeting myeloid-derived suppressor cells in combination with primary mammary tumor resection reduces metastatic growth in the lungs","volume":"21","author":"Bosiljcic","year":"2019","journal-title":"Breast Cancer Res"},{"key":"2026052723003309000_13.5.e011398.21","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0903670"},{"key":"2026052723003309000_13.5.e011398.22","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/nature10491","article-title":"An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor","volume":"478","author":"Opitz","year":"2011","journal-title":"Nature New Biol"},{"key":"2026052723003309000_13.5.e011398.23","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1007\/s00109-015-1304-0","article-title":"Aryl hydrocarbon receptor agonists upregulate VEGF secretion from bronchial epithelial cells","volume":"93","author":"Tsai","year":"2015","journal-title":"J Mol Med (Berl)"},{"key":"2026052723003309000_13.5.e011398.24","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-020-17750-z","article-title":"Blockade of the AHR restricts a Treg-macrophage suppressive axis induced by L-Kynurenine","volume":"11","author":"Campesato","year":"2020","journal-title":"Nat Commun"},{"key":"2026052723003309000_13.5.e011398.25","doi-asserted-by":"publisher","DOI":"10.1124\/mol.105.021832"},{"key":"2026052723003309000_13.5.e011398.26","doi-asserted-by":"publisher","DOI":"10.1016\/S0223-5234(01)01253-3"},{"key":"2026052723003309000_13.5.e011398.27","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-020-0413-z"},{"key":"2026052723003309000_13.5.e011398.28","doi-asserted-by":"crossref","DOI":"10.1148\/rycan.220138","article-title":"PET\/MRI and Bioluminescent Imaging Identify Hypoxia as a Cause of Programmed Cell Death Ligand 1 Image Heterogeneity","volume":"5","author":"Parkins","year":"2023","journal-title":"Radiol Imaging Cancer"},{"key":"2026052723003309000_13.5.e011398.29","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1718197115"},{"key":"2026052723003309000_13.5.e011398.30","doi-asserted-by":"crossref","first-page":"366","DOI":"10.3389\/fimmu.2020.00366","article-title":"Therapy With Carboplatin and Anti-PD-1 Antibodies Before Surgery Demonstrates Sustainable Anti-Tumor Effects for Secondary Cancers in Mice With Triple-Negative Breast Cancer","volume":"11","author":"Gao","year":"2020","journal-title":"Front Immunol"},{"key":"2026052723003309000_13.5.e011398.31","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/s41416-022-02041-9","article-title":"How the histological structure of some lung cancers shaped almost 70 years of radiobiology","volume":"128","author":"Worth","year":"2023","journal-title":"Br J Cancer"},{"key":"2026052723003309000_13.5.e011398.32","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2016.04.009"},{"key":"2026052723003309000_13.5.e011398.33","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.700407"},{"key":"2026052723003309000_13.5.e011398.34","doi-asserted-by":"publisher","DOI":"10.1038\/s41580-020-0270-8"},{"key":"2026052723003309000_13.5.e011398.35","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-024-00920-9"},{"key":"2026052723003309000_13.5.e011398.36","doi-asserted-by":"publisher","DOI":"10.1038\/s41422-020-0383-9"},{"key":"2026052723003309000_13.5.e011398.37","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12092637","article-title":"Immunogenic Cell Death and Elimination of Immunosuppressive Cells: A Double-Edged Sword of Chemotherapy","volume":"12","author":"Fumet","year":"2020","journal-title":"Cancers (Basel)"},{"key":"2026052723003309000_13.5.e011398.38","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.1637"},{"key":"2026052723003309000_13.5.e011398.39","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-51537-7","article-title":"Drug-induced PD-L1 expression and cell stress response in breast cancer cells can be balanced by drug combination","volume":"9","author":"Gilad","year":"2019","journal-title":"Sci Rep"},{"key":"2026052723003309000_13.5.e011398.40","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1200\/JCO.19.03022","article-title":"Therapy for Stage IV Non-Small-Cell Lung Cancer Without Driver Alterations: ASCO and OH (CCO) Joint Guideline Update","volume":"38","author":"Hanna","year":"2020","journal-title":"J Clin Oncol"},{"key":"2026052723003309000_13.5.e011398.41","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-017-3473-8"},{"key":"2026052723003309000_13.5.e011398.42","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1111\/jcpt.13534","article-title":"The efficacy and toxicity of maintenance therapy with bevacizumab plus pemetrexed versus bevacizumab\/pemetrexed alone for stage IIIB\/IV nonsquamous non-small cell lung cancer: A meta-analysis of randomized controlled trials","volume":"47","author":"Liu","year":"2022","journal-title":"J Clin Pharm Ther"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2024-011398","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T06:00:43Z","timestamp":1779948043000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2024-011398"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":42,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,5,30]]},"published-print":{"date-parts":[[2025,5]]}},"alternative-id":["10.1136\/jitc-2024-011398"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2024-011398","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5]]}}}